|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplementary Table 3. Univariate biomarker analysis in non endometrioid subtype cohort** | | | | | |
| Variable | Descriptive | RFS | | OS | |
|  | n (%) | HR (95%CI) | p-value | HR (95%CI) | p-value |
| ER  Negative  Positive  NE | 26 (74.3)  8 (22.9)  1 (2.9) | 0.83 (0.23 – 2.94) | 0.76 | 0.61 (0.13 – 2.78) | 0.52 |
| PR  Negative  Positive  NE | 25 (71.4)  9 (25.7)  1 (2.9) | 1.07 (0.34 – 3.39) | 0.90 | 0.86 (0.23 – 3.20) | 0.83 |
| ECAD  Negative  Positive  NE | 12 (34.3)  18 (51.4)  5 (14.3) | 0.49 (0.16 – 1.40) | 0.18 | 0.25 (0.06 – 1.01) | 0.05 |
| HER2  Negative  Positive  NE | 32 (91.4)  2 (5.7)  1 (2.9) | 0.60 (0.07 – 4.60) | 0.62 | NE | NE |
| ARID1A  Negative  Positive  NE | 29 (82.9)  6 (17.1)  - | 1.44 (0.46 – 4.50) | 0.53 | 1.53 (0.41 – 5.70) | 0.53 |
| PTEN  Negative  Positive  NE | 19 (54.3)  15 (42.9)  1 (2.9) | 0.53 (0.19 – 1.48) | 0.23 | 0.48 (0.14 – 1.61) | 0.23 |
| L1CAM  Negative  Positive  NE | 13 (37.1)  20 (57.1)  2 (5.7) | 0.32 (0.11 – 0.99) | 0.05 | 0.28 (0.0.7 – 1.09) | 0.07 |
| *CTNNB1*  Non mutated  Mutated  NE | 34 (97.1)  1 (2.9) | NE | NE | NE | NE |
| NE: Not evaluable; HR: Hazard ratio; 95%CI: 95% Confidence interval; RFS: Relapse-free survival; OS: Overall survival. | | | | | |